α-Pinene and β-Pinene as Natural Adjuvants Against MRSA: Evidence from in vivo Models and Molecular Docking
Current Microbiology · 2026
DOI: 10.1007/s00284-025-04593-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift Current Microbiology, 2026. Verfasst von Amanda Vieira de Barros und 12 weiteren Autor:innen. Beteiligte Einrichtung: Centro de Biociências, Departamento de Bioquímica, Universidade Federal de Pernambuco, Recife, Brazil. Hauptthemen laut MEDLINE: Bicyclic Monoterpenes, Anti-Bacterial Agents, Methicillin-Resistant Staphylococcus aureus, Staphylococcal Infections. Die Arbeit nennt 60 Literaturangaben.
Abstract (Originalsprache)
Staphylococcus aureus is a major pathogen in Healthcare-Associated Infections (HAIs), with antibiotic resistance and virulence factors that hinder treatment and reduce therapeutic options. Natural terpenes such as α-pinene (APN) and β-pinene (BPN) have emerged as potential modulators of bacterial resistance. This study assessed the antibacterial and antivirulence activities of APN and BPN, alone and in combination with antibiotics, against S. aureus. The Minimum Inhibitory Concentrations (MICs) of the selected terpenes and antibiotics were defined by the broth microdilution method, and synergistic interactions were determined by checkerboard assays, followed by growth kinetics, time-kill curves, and antivirulence assays targeting biofilm formation, coagulase activity, and hemolysin production. In vivo toxicity, bacterial burden, and host survival were evaluated using the Galleria mellonella model. Both compounds exhibited MICs ranging from 64 to 4,096 µg/mL, with BPN showing pronounced synergy with amoxicillin (BPA) and oxacillin (BPO). The BPO combination reduced bacterial load by 82.1% and more effectively inhibited virulence factors than APN. In silico analyses supported these findings, revealing strong interactions between pinenes and key bacterial targets. No toxicity was observed in vivo. These results highlight BPN as a promising adjuvant candidate to enhance β-lactam efficacy against S. aureus, supporting integrated antibacterial and antivirulence strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Centro de Biociências, Departamento de Bioquímica, Universidade Federal de Pernambuco, Recife, Brazil.
- Universidade Federal do Rio Grande do Norte, Ambiente Multidisciplinar de Bioinformática, Rio Grande do Norte, Brazil.
- Departamento de Física Aplicada, Universidade de Campinas, Campinas, São Paulo, Brazil.
- Centro de Biociências, Departamento de Antibióticos, Universidade Federal de Pernambuco, Recife, Brazil.
- Departamento de Química Biológica, Universidade Regional do Cariri, Crato - CE, Brazil. hdmcoutinho@gmail.com.
Zitieren
APA
de Barros, A. V., de Veras, B. O., de Lima Menezes, G., Bezerra, K. S., Mendes, R. F. V., Dos Santos, P. É. M., Ximenes, R. M., Fulco, U. L., Galvão, D. S., Paiva, P. M. G., da Silva, M. V., Coutinho, H. D. M., & de Oliveira, M. B. M. (2026). α-Pinene and β-Pinene as Natural Adjuvants Against MRSA: Evidence from in vivo Models and Molecular Docking. Current Microbiology. https://doi.org/10.1007/s00284-025-04593-4
Vancouver
de Barros AV, de Veras BO, de Lima Menezes G, Bezerra KS, Mendes RFV, Dos Santos PÉM, et al. α-Pinene and β-Pinene as Natural Adjuvants Against MRSA: Evidence from in vivo Models and Molecular Docking. Current Microbiology. 2026. doi:10.1007/s00284-025-04593-4
BibTeX
@article{deBarros2026,
author = {de Barros, Amanda Vieira and de Veras, Bruno Oliveira and de Lima Menezes, Gabriela and Bezerra, Katyanna Sales and Mendes, Raudiney Frankilin Vasconcelos and Dos Santos, Patryck Érmerson Monteiro and Ximenes, Rafael Matos and Fulco, Umberto Laino and Galvão, Douglas Soares and Paiva, Patrícia Maria Guedes and da Silva, Márcia Vanusa and Coutinho, Henrique Douglas Melo and de Oliveira, Maria Betânia Melo},
title = {α-Pinene and β-Pinene as Natural Adjuvants Against MRSA: Evidence from in vivo Models and Molecular Docking},
journal = {Current Microbiology},
year = {2026},
doi = {10.1007/s00284-025-04593-4}
}
EUVIMED